Free Trial
NASDAQ:QTTB

Q32 Bio Q1 2025 Earnings Results & Report

Q32 Bio logo
$8.71 -0.11 (-1.25%)
Closing price 11/13/2026 04:00 PM Eastern
Extended Trading
$8.72 +0.01 (+0.11%)
As of 11/13/2026 07:57 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Q32 Bio beat analyst earnings expectations in its Q1 2025 results, released May 8, 2025. The company reported EPS of -$0.90 versus the -$1.23 consensus estimate.

Earnings Announcement Details

Quarter
Q1 2025
Report Date
Time
Before Market Opens
Conference Call
7:00 AM ET

Q32 Bio EPS Results

Actual EPS
-$0.90
Consensus EPS
-$1.23
Beat/Miss
Beat by +$0.33
One Year Ago EPS
N/A
EPS Beat Rate
8 of last 8 quarters

Q32 Bio Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Q32 Bio Q1 2025 Earnings FAQ

Q32 Bio (NASDAQ:QTTB) reported earnings of -$0.90 per share for Q1 2025, beating the consensus estimate of -$1.23. The report was announced on Thursday, May 8, 2025.

Q32 Bio Earnings Headlines

My public warning after 55 years of watching the markets
Dr. Martin D. Weiss has publicly predicted six major American market crashes over his 55-year career, each warning issued before the crisis hit. Now the founder of Weiss Ratings, the only conflict-free rating agency in America, says he is watching a $3 trillion problem that could trigger a chain reaction across markets and banks.tc pixel
Jefferies Keeps Their Buy Rating on Q32 Bio (QTTB)
See More Q32 Bio Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Q32 Bio? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Q32 Bio and other key companies, straight to your email.

About Q32 Bio

Q32 Bio (NASDAQ:QTTB) is a biotechnology company focused on developing treatments for autoimmune and inflammatory diseases by targeting pathways that regulate the immune system. Its research has centered on biologic medicines designed to restore immune balance and address disease mechanisms.

The company’s programs have included ADX-097, a complement C3 inhibitor designed to target activity in affected tissues, and ADX-914, an antibody targeting the interleukin-7 receptor alpha. Q32 Bio has been based in the United States and has advanced its programs through clinical development.

Q32 Bio became a publicly traded company in 2024 through a business combination with Homology Medicines. The combined company retained the Q32 Bio name and trades on the Nasdaq under the symbol QTTB.

View Q32 Bio Profile